The week is just getting started, and Tilray already has more news to share with the world. It’s not the largest cannabis company in the world for nothing. Tilray, considered the world’s pioneer in medical cannabis research, cultivation, production and distribution, recently announced that the Luxembourg Ministry of Health has chosen it as the supplier of Good Manufacturing Practice (GMP) certified medical cannabis products for the country’s medical cannabis program. It is certainly one of the many recent achievements the company has been able to hang in its target room.
Tilray, upon receiving these honors and being selected by the City Health Department, will be responsible for supplying a wide range of its pharmaceutical grade medical cannabis products, including dried flowers and extracts with different levels of cannabidiol (CBD) and tetrahydrocannabinol (THC) for patients currently suffering from various pathologies. Prescription medical cannabis products will be administered to patients, as long as they have gone through the respective process and have been certified by Luxembourg physicians.
“We believe that Tilray’s growth potential in the European Union represents a $1 billion opportunity, and today’s announcement affirms that we are turning potential into performance,” said Irwin D. Simon, CEO and president of Tilray. “With today’s validation from the Luxembourg Ministry of Health, Tilray now offers branded medical cannabis in 20 countries around the world — a testament to our high standards and status as a trusted partner to patients in need. We’re proud to be building this unrivaled global platform and will continue to advocate for patient access in Europe and countries around the world.”
Tilray currently operates two GMP-certified cultivation facilities in Europe, located in Neumunster, Germany and Cantanhede, Portugal. Over the past few months, the company has been doing everything necessary to establish sales and distribution agreements to supply medical cannabis through the most relevant pharmaceutical distribution channels in the market, including CC Pharma, throughout Germany and the EU. As a result, patients will have easier access to Tilray’s GMP-certified finished medical cannabis.